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Abstract: Basiliximab is a chimeric mouse-human monoclonal antibody directed against the 
alpha chain of the interleukin-2 (IL-2) receptor on activated T lymphocytes. It was shown in 
phase III trials to reduce the number and severity of acute rejection episodes in the ﬁ  rst year 
following renal transplantation in adults and children, with a reasonable cost-beneﬁ  t ratio. The 
drug does not increase the incidence of opportunistic infections or malignancies above baseline 
in patients treated with conventional calcineurin inhibitor-based immunosuppression. In the ﬁ  eld 
of renal transplantation, basiliximab does not increase kidney or patient survival, despite the 
reduction in the number of rejection episodes. Basiliximab may reduce the incidence of delayed 
graft function. In comparison with lymphocyte-depleting antibodies basiliximab appears to have 
equal efﬁ  cacy in standard immunological risk patients. Recently, IL-2 receptor monoclonal 
antibodies have been used with the objective of reducing or eliminating the more toxic elements 
of the standard immunosuppression protocol. Several trials have incorporated basiliximab in 
protocols designed to avoid or withdraw rapidly corticosteroids, as well as protocols which 
substitute target-of-rapamycin (TOR) inhibitors for calcineurin inhibitors.
Keywords: basiliximab, renal transplantation, IL-2 receptor antagonists, induction, immuno-
suppression, corticosteroids, calcineurin inhibitors
In the decades that followed the ﬁ  rst successful kidney transplant in 1954, the stan-
dard immunosuppression protocols for solid organ transplantation have evolved to 
permit reliable short-term graft survival, such that transplantation has become the 
preferred therapy for end-stage organ failure. In the case of renal transplantation, 
graft and patient survival exceed 90% during the ﬁ  rst post-transplant year. Neverthe-
less, long-term graft survival rates, although improving, have not kept pace with the 
success of short-term rejection prevention. For recipients of standard deceased donor 
kidneys performed between 2001 and 2002 unadjusted one-year graft survival was 
91%, and for the period 1997–1998 ﬁ  ve-year graft survival was 69%; for the same 
time periods, unadjusted ﬁ  ve-year graft survival for expanded criteria donors was 
51% (2004 OPTN/SRTR Annual Report). In addition, the pillars of the standard 
immunosuppression protocols – calcineurin inhibitors, corticosteroids and adjuvant 
antimetabolites such as azathioprine and mycophenolate mofetil (MMF) – are associ-
ated with collateral infectious, neoplastic and metabolic effects which not only lead 
to organ damage, but also may contribute to the premature patient mortality with a 
functioning graft that afﬂ  icts all organ transplants. Thus, the past decade has been 
characterized by attempts to modify the standard protocol to maintain excellent short-
term transplant survival, prolong organ half-life, and reduce the dependence on the 
more toxic immunosuppressants.
The purpose of this review is to describe the role of IL-2 receptor monoclonal 
antibodies – speciﬁ  cally basiliximab – in the context of this evolving paradigm of Biologics: Targets & Therapy 2008:2(2) 176
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standard immunosuppression, with an emphasis on renal 
transplantation. Several useful reviews on the use of basil-
iximab in renal transplantation are available in the literature 
(Chapman and Keating 2003; Swiatecka-Urban 2003; Boggi 
et al 2004; Ramirez and Marino 2007). The main interest 
of the present work is to demonstrate how basiliximab is 
currently being used to modify standard calcineurin inhibi-
tor- and corticosteroid-based protocols, particularly from 
the practical nephrological viewpoint. This review is based 
on a search of Medline and the Cochrane data bases using 
the MeSH terms “basiliximab” and “renal transplantation” 
as of January 30, 2007. The aim of the literature search was 
to ﬁ  nd all randomized controlled studies which incorporated 
basiliximab in the study protocols. Additional articles were 
selected on the basis of relevance to speciﬁ  c topics.
Drug development 
and pharmacological properties
Several interesting reviews discuss the development of basi-
liximab as an induction therapy for organ transplantation 
(Morris and Waldmann 2000; Pascual et al 2001; Church 
2003). The T lymphocyte IL-2 receptor is composed of three 
subunits: a small (55 kD) speciﬁ  c α chain (also known as 
CD25), a 75 kD β chain (CD122) and a 64 kD γ chain (CD132) 
(Morris and Waldmann 2000). The CD25 molecule presented 
itself as a tempting target for drug development, due to its IL-2 
speciﬁ  city and its presence only on T cells preactivated with 
other cytokines, such as IL-1, IL-6, and tumor necrosis factor. 
Eliminating the cells which bear the CD25 molecule would 
block downstream events leading to organ rejection, without 
damaging bystander cells not involved in the rejection process, 
and therefore reduce unwanted collateral effects – infections 
and tumors – secondary to over-immunosuppression.
The α subunit of the IL-2 receptor complex was discov-
ered by developing a murine monoclonal antibody against 
activated T cells, known as anti-Tac (Uchiyama et al 1981). 
The clinical use of the antibody in animal models, however, 
was hampered by efficacy defects and side effects. To 
overcome these problems, the murine variable region of the 
IgG molecule was fused to the human constant region, thus 
reducing the immunogenicity of the antibody, prolonging the 
half-life and improving the interaction with human effector 
molecules and cells (Queen et al 1989). Two antibodies 
have been constructed and produced by recombinant DNA 
techniques from mouse myeloma cell lines: basiliximab, a 
chimeric monoclonal antibody which includes the entire 
murine variable region and is approximately 80% human, 
and daclizumab, a humanized monoclonal antibody which 
includes only the hypervariable murine component and is 
approximately 90% human. Both drugs are currently on the 
market with trade names of Simulect (basiliximab, Novartis) 
and Zenapax (daclizumab, Roche) and have shown virtu-
ally the same results in phase III clinical trials, although a 
randomized, prospective, well-powered study between the 
two drugs using the currently recommended dosage schedules 
has not been performed.
Three phase II trials performed in deceased donor kidney 
recipients (Amlot et al 1995; Kovarik et al 1996; Kovarik 
et al 1997) demonstrated that basiliximab is not associated 
with cytokine release phenomena during drug infusion, rarely 
causes allergic reactions to the murine protein, is endowed 
with a prolonged half-life in the standard dose, provides 
effective receptor saturation for 4–6 weeks after transplanta-
tion, and pharmacokinetic parameters are not affected by sex 
or weight in recipients weighing more than 35 kilograms. 
No treatment beneﬁ  t was found when activated lymphocytes 
bearing the IL-2 α chain were suppressed for longer than 
one month (Amlot et al 1995). Importantly, the phase II data 
established that serum basiliximab concentrations exceeding 
0.2 μg/ml were sufﬁ  cient to saturate CD25 on circulating T 
lymphocytes in vivo. Interestingly, the phase II studies were 
carried out to determine the antibody dose during the ﬁ  rst 
four to six weeks post-transplant which could achieve this 
concentration. This dose was found to be 40 mg, and it was 
decided to divide the total dose into two 20 mg subdoses, one 
infused immediately before surgery and the other adminis-
tered on day 4, in order withhold the second dose in case of 
technical failure in the ﬁ  rst days post-transplant (Pascual et al 
2001). This simple dosing schedule allows all of the drug to 
be administered during the hospitalization. In addition, all 
subsequent clinical trials were based on this dosing schedule, 
which enhanced reproducibility.
Pharmacokinetic modeling was also performed in the 
pediatric age group (Kovarik et al 2002); the recommended 
dosage for patients weighing less than 35 kg is two doses of 
10 mg, the ﬁ  rst two hours before surgery and the second on 
day 4, while those patients weighing more than 35 kg should 
receive the standard two 20 mg doses. Importantly, it was 
also shown that cyclosporin blood levels may be signiﬁ  cantly 
increased in children by concomitant administration of 
basiliximab compared to controls (Strehlau et al 2000). As 
basiliximab levels declined, there were parallel reductions 
in the cyclosporin levels, requiring increased doses of the 
calcineurin inhibitor to maintain therapeutic trough levels.
Also in adults basiliximab may provoke drug interactions 
with calcineurin inhibitors. Sifontis and colleagues (2002) Biologics: Targets & Therapy 2008:2(2) 177
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noted signiﬁ  cantly elevated tacrolimus trough levels in 
patients treated with basiliximab during the four days of 
treatment, compared to controls who received no basiliximab. 
This observation suggested that basiliximab may induce 
alterations of the cytochrome P450 pathway in the liver, 
which is responsible for the metabolism of both cyclosporin 
and tacrolimus. Nevertheless, because this hypothesized 
interaction has not been proven, there are no speciﬁ  c recom-
mendations of altering calcineurin inhibitor doses during 
basiliximab administration. Both mycophenolate mofetil 
(MMF) and azathioprine also alter basiliximab pharmaco-
kinetics (Kovarik et al 2001); but the clinical consequences 
of these drug interactions are unclear, and also for these 
drugs there are no indications for modifying the standard 
doses of the drugs.
Population pharmacokinetics were again determined 
during the ﬁ  rst large phase III blinded, randomized, placebo-
controlled trial in adults (Kovarik et al 1999). The result of 
the trial in 169 treated patients was that no special popula-
tions, based on sex, weight, ethnicity, and proteinuria, were 
not adequately treated with the standard dosing regimen. 
Speciﬁ  cally, it was found that the elimination half-life was 
approximately one week, that hemodialysis did not affect 
half-life, and on the average receptor-saturating concentra-
tions were maintained for 36 ± 14 days. Interestingly, patients 
who suffered an acute rejection had not cleared basiliximab 
faster than their counterparts who remained rejection-free to 
month 6 post-transplant, nor was the duration of CD25 satu-
ration different between the two groups. Saturation duration 
was not different between groups according to the severity 
scores of the rejection (Banff grades). The mean duration of 
IL-2R α saturation in pediatric patients receiving basiliximab 
12 mg/m2 of 10 or 20 mg, depending on bodyweight, was 
31–42 days (Sterkers et al 2000; Kovarik et al 2002).
There are relatively few reports that investigate the 
pharmacokinetics of basiliximab during extracorporeal renal 
replacement therapy. Eguchi and colleagues (2004) studied 
serum levels in a liver transplant recipient who was main-
tained on continuous hemodiaﬁ  ltration (CVVHDF using a 
polymethylmethacrylate ﬁ  lter) throughout the perioperative 
period until he died on the thirtieth post-operative day. Serum 
levels of basiliximab remained within the therapeutic range 
( 200 ng/ml) at least until post-op day 28, and did not differ 
from a control patient who was not treated with CVVHDF. 
CD25 positive cells were appropriately surpressed. However, 
the concentration of basiliximab is reduced by more than 
60% by a single session of plasmapheresis (Okechukwu et al 
2001) or nearly 90% by multiple sessions (Nojima et al 2005). 
Massive proteinuria may also signiﬁ  cantly reduce antibody 
concentrations (Nagai et al 2005).
The role of induction therapy 
in renal transplantation
We have reviewed how IL-2R antagonists, including basil-
iximab, have been developed, but before describing the tens 
of studies that have been performed to determine the efﬁ  cacy 
of this class of pharmaceuticals, it may be useful to explain 
why they were developed, particularly in reference to their 
role as inducing agents.
In the ﬁ  eld of renal transplantation, the term induction 
refers to a period of intense immunosuppression immediately 
before and following the implant of the allograft. This intense 
immunosuppression usually consists of bolus administration of 
corticosteroids and relatively high dosages of the calcineurin 
inhibitors – cyclosporin or tacrolimus – to achieve elevated 
blood concentrations in the perioperative period. These drugs, 
together with an antiproliferative agent, such as azathioprine 
or mycophenolate mofetil (MMF), constitute the classic “triple 
therapy” that now characterizes solid organ transplantation and 
has led to consistent patient and graft survival rates in the ﬁ  rst 
transplant year, exceeding 90% for the kidney. The induction 
period typically lasts 4–6 weeks following transplantation; the 
dosages of the immunosuppressive drugs are then tapered to 
lower doses, which constitutes the maintenance phase of immu-
nosuppression, lasting as long as the allograft survives. The 
rationale for more intense immunosuppression immediately 
following the transplant procedure derives from the observation 
that reactive recipient lymphocytes recognize antigen-present-
ing cells (APCs) of donor origin differently than the recognition 
that follows when antigen is presented by the recipient’s own 
APCs. When an immune response is mounted against a com-
mon pathogen, such as a virus or tumor particle, the antigen 
must be presented bound to the host’s HLA to be recognized by 
a speciﬁ  c clone of T cells (indirect recognition or HLA restric-
tion). The unique aspect of transplant immunology, on the other 
hand, is that the recipient’s T cells recognize the entire HLA 
complex of the donor’s APCs as foreign (direct recognition), 
and the brisk rejection reaction that follows results from the fact 
that many more T lymphocyte clones with varying speciﬁ  ci-
ties—two-per-hundred T cells, in comparison with one-per-ten 
thousand which respond to common environmental antigens 
(Auchinloss 1995)—recognize the foreign HLA present on the 
donor’s APCs. With time the donor’s APCs are replaced by 
those of the recipient and perhaps local suppressor phenomena 
occur which modulate the immune response, and the doses of 
immunosuppression can be safely lowered.Biologics: Targets & Therapy 2008:2(2) 178
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Until the introduction of cyclosporin in the mid-1980’s, 
only corticosteroids and azathioprine were available for 
immunosuppression, and the half-life of the transplanted 
kidney was approximately 12 months. In 1967 equine 
antilymphocyte globulin was cautiously introduced as an 
adjuvant immunosuppressant, despite fears of serum sickness 
and anaphylactic reactions (Brent 1997). Induction with these 
early antilymphocyte globulins was associated with fewer 
rejection episodes; but the production of antilymphocyte 
globulin was often a local, nonstandardized affair, and the 
results with these drugs, sometimes very good, were not 
reproducible between and within transplant centers. The 
greater efﬁ  cacy of cyclosporin, which has increased the 
transplanted kidney half-life several fold, led to the phasing 
out of these early inducing agents.
According to the Organ Procurement and Transplanta-
tion Network (OPTN) data, the use of induction therapy has 
increased steadily throughout the last decade; 72% of kidney 
transplant recipients are now treated with induction immu-
nosuppression, compared to 46% in 1995 (Meier-Kriesche 
et al 2006). What, then, has motivated the introduction of new 
inducing agents in the ﬁ  eld of renal transplantation, given 
the relative success of calcineurin inhibitors? Firstly, not all 
patient populations have shared in the improved outcomes 
furnished by standard triple therapy, including those at risk 
for delayed graft function, highly sensitized patients, African-
Americans, patients with chronic hepatitis C or B infections, 
patients with systemic disease such as diabetes mellitus and 
others. With the introduction of new immunosuppressants 
including induction agents, it is becoming possible to tailor 
the immunosuppressive protocol to the needs of the individ-
ual patient. Secondly, after the introduction of standard triple 
therapy, it soon became clear that collateral effects limited 
not only graft survival due to nephrotoxicity, but also patient 
survival was not commensurate with the general population, 
perhaps due to infectious, oncologic and metabolic effects 
of the standard immunosuppressants. Thus, it behooved the 
transplant community to seek ways to reduce or substitute 
the more toxic elements of the standard protocol, particu-
larly corticosteroids and the calcineurin inhibitors. Finally, 
the pharmaceutical industry has introduced puriﬁ  cation and 
standardization features to polyclonal antilymphocyte prepa-
rations which has increased efﬁ  cacy and reproducibility, 
efﬁ  cacious antiviral prophylaxis which allows the consid-
eration of enhanced immunosuppression, the production of 
pure humanized monoclonal antibodies such as the IL-2R 
antagonists with the promise of more targeted immunosup-
pression and safety, and aggressive marketing.
As mentioned previously, local suppressor phenomena 
may have a role in dampening the rejection reaction in time. 
In fact, great interest has been generated by the discovery 
that naturally arising regulatory T lymphocytes (Tregs) 
actively maintain immunological self-tolerance (Sakaguchi 
2005). These cells, which are characterized by expression of 
the surface antigens CD4 and particularly CD25, are associ-
ated with a transcription factor, FOXP3, which is necessary 
for the expression of the key suppressor gene responsible 
for the CD4+CD25+ phenotype. It has been hypothesized 
that these suppressor T cells modulate cellular rejection, 
and that expansion of antigen-speciﬁ  c clones of Tregs 
may actually lead to peripheral transplantation tolerance. 
Thus, these important regulatory lymphocytes constitute 
the small fraction of CD25-positive T cells in the circula-
tion not correlated with immune activation. Could IL-2R 
antagonists, then, also reduce the population of Tregs during 
induction therapy, and thus reduce the host’s capacity to 
modulate the rejection response per se? Baan and colleagues 
(2005) have found that monoclonal anti-CD25 antibodies 
(in this case, daclizumab) do, in fact, reduce FOXP3 mes-
senger RNA levels in vitro. On the other hand, Game and 
colleagues (2005) found that the suppressor functions of 
human CD4+CD25+ T cells were not diminished in the pres-
ence of everolimus or basiliximab – always in vitro – and 
were, in fact, resistant to the pro-apoptotic effects of the 
immunosuppressors. The clinical signiﬁ  cance of these ﬁ  nd-
ings is yet to be determined.
Human efﬁ  cacy studies
The success of basiliximab in the phase I and II trials led 
to two large scale, randomized, blinded, placebo-controlled 
phase III efﬁ  cacy trials, one in the United States (Kahan et al 
1999) and the other in Europe and Canada (Nashan et al 
1997). Both trials studied basiliximab in combination with 
cyclosporin microemulsion and corticosteroids using standard 
protocols and drug level monitoring. The principal outcome 
variable was acute rejection occurring in the ﬁ  rst six months 
and 12 months in the European study and 12 months in the 
American study. Patient and graft survival were secondary 
outcome variables. A total of 722 patients were analyzed 
in the two studies, evenly divided between treated patients 
and controls, on an intention-to-treat basis. In both studies 
basiliximab was shown to reduce signiﬁ  cantly the incidence 
of acute rejection at 12 months (in the US study: placebo 
54.9%, basiliximab 37.6%, p   0.001; in the European 
study: placebo 54.8%, basiliximab 37.9%, p   0.01). Basi-
liximab was associated with signiﬁ  cantly fewer episodes of Biologics: Targets & Therapy 2008:2(2) 179
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corticosteroid-resistant rejection requiring antilymphocyte 
therapy, and placebo-treated patients required signiﬁ  cantly 
greater amounts of corticosteroids than basiliximab-treated 
patients at week 2. Neither study showed signiﬁ  cant differ-
ences in graft or patient survival at 12 months. In the US 
study, a signiﬁ  cantly higher proportion of patients produced 
urine in the operating room compared with patients receiving 
placebo. Thus, the incidence of delayed graft function was 
lower in patients treated with basiliximab (15%) than those 
treated with placebo (23%, p = 0.07), although there were 
no differences between groups for the need of hemodialysis 
within the ﬁ  rst postoperative week. Also in the US study, the 
sum of adverse events including graft loss, patient death and 
rejection was lower in the recipients receiving basiliximab 
(41.0% vs 58.4%, p = 0.001). Graft survival was enhanced 
in African American patients who were treated with basilix-
imab at six months (100% vs 92%, p = 0.041) and at twelve 
months (98% vs 88%, p = 0.059). In the American study, 
there was no statistical difference in the incidence of acute 
rejection between basiliximab and placebo among recipients 
of live donor kidneys.
Pooled data from the two large phase III trials were 
used to assess the efﬁ  cacy of basiliximab in patients with 
type 1 and type 2 diabetes (Thistlethwaite et al 2000). 
A total of 80 patients were treated with basiliximab and 
70 patients received placebo. Basiliximab treatment was 
associated with a signiﬁ  cant reduction of acute rejection 
and biopsy-conﬁ  rmed rejection (by 41% and 44%, respec-
tively). Basiliximab was also associated with signiﬁ  cantly 
better graft survival compared with placebo (96% vs 86%, 
p = 0.022).
Long-term unblinded follow-up data from these two 
seminal studies have been pooled for the original 722 patients 
by the manufacturer of basiliximab (Chapman and Keating 
2003). Signiﬁ  cantly more basiliximab recipients were free 
from the combined endpoint of death, graft loss or acute 
rejection at three years, compared with the patients who 
had been treated with placebo, as assessed by Kaplan Meier 
curves (53% vs 45%, p = 0.025). However, this difference 
had equalized by ﬁ  ve years following transplantation.
These two phase III efﬁ  cacy trials were swiftly fol-
lowed by three additional multicenter, randomized, blinded, 
placebo-controlled studies in which basiliximab was com-
pared to placebo in patients treated with standard triple immu-
nosuppression including azathioprine (Ponticelli et al 2001; 
de Boccardo 2002) or mycophenolate mofetil (MMF; Lawen 
et al 2003). Also in these carefully performed trials, which 
included a total of 766 patients, basiliximab demonstrated 
superior prophylaxis of acute rejection compared with 
placebo, without affecting graft or patient survival rates at 
six and twelve months. Three-year (Sheashaa et al 2003) and 
ﬁ  ve-year (Sheashaa et al 2005) follow-up of 100 recipients 
of live donor kidneys is available from a single center, in 
which patients were randomized to treatment with basilix-
imab or no induction in combination with standard triple 
immunosuppression with azathioprine. The results were 
comparable to the studies cited above: the incidence of 
acute rejection at ﬁ  ve years was reduced in patients treated 
with basiliximab (54% vs 72%, p = 0.062), but incidence of 
chronic allograft nephropathy, graft function as assessed by 
creatinine or creatinine clearance, graft and patient survival 
did not differ between the two groups after three years. The 
cumulative steroid dose was lower in patients treated with 
basiliximab (p = 0.027).
Most of these early studies utilized cyclosporin as the 
calcineurin inhibitor. Leonardi and colleagues (2004) retro-
spectively analyzed their results using basiliximab (n = 51) 
versus no induction (n = 46) in association with dual immuno-
suppression with tacrolimus and corticosteroids. A signiﬁ  cant 
decrease in acute rejection in the ﬁ  rst three months in the 
basiliximab group (2% vs 17.4%, p   0.01) was observed, 
despite greater immunological risk. Hospital stay was also 
signiﬁ  cantly shorter in the basiliximab group.
Efﬁ  cacy studies in children
Several small retrospective studies are available which 
compare basiliximab with no induction in the pediatric 
population treated with dual therapy calcineurin inhibitor 
and corticosteroids (Swiatecka-Urban et al 2001; Vester et al 
2001; Pape et al 2002) or triple therapy (Ojogho et al 2005). 
No statistical differences were observed between groups in 
terms of acute rejection or graft or patient survival in the 
12 months following transplantation, although Swiatecka-
Urban and colleagues (2001) found a clear advantage when 
basiliximab was used in patients at high risk for rejection or 
delayed graft function.
Recently, Grenda and colleagues (2006) reported the 
results of a prospective, randomized, multicenter trial of 
basiliximab (n = 99) versus no induction (n = 93) in a tacro-
limus-based protocol that included azathioprine and corti-
costeroids for standard-risk patients  18 years of age who 
received kidney transplants. Acute rejection rates, steroid-
resistant rejection rates, patient and graft survival, and renal 
function were virtually identical between the two groups at 
six months. Adverse events were similar in both groups in 
terms of type and frequency, although “toxic nephropathy” Biologics: Targets & Therapy 2008:2(2) 180
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(apparently tacrolimus-induced) and abdominal pain were 
observed signiﬁ  cantly more frequently in the basiliximab 
group. Delayed graft function and CMV infections were 
insigniﬁ  cantly more frequent in the basiliximab group. 
Offner and colleagues (2006) have also reported the results 
of a randomized, multicenter, placebo-controlled trial com-
paring the efﬁ  cacy and safety of basiliximab with no induc-
tion in 202 children, in association with cyclosporin, MMF 
and corticosteroids. The incidence of biopsy-proven acute 
rejection at six months was 11% in the basiliximab group 
and 16.1% in the placebo group (NS). The overall incidence 
of adverse events was also similar in the two groups.
Efﬁ  cacy in the elderly
There are relatively few data available to assess the effect 
of basiliximab on kidney transplant recipients  60 years of 
age. As part of a retrospective study comparing muromonab 
CD3 vs basiliximab induction and triple therapy, Kode and 
colleagues (2003) compared the outcome at three months 
post-transplant in patients younger or older than 60 years of 
age in those receiving basiliximab. Despite signiﬁ  cantly more 
HLA mismatches and older donor age, the older recipients 
fared as well as younger patients in terms of acute rejection, 
severity of rejection, graft survival, patient survival, hospital 
stay and serum creatinine (p = 0.13). Heifets et al (2004) 
analyzed their data on 183 consecutive kidney transplant 
recipients  60 years of age over a 12-year period during 
which four cohorts could be recognized on the basis of the 
induction therapy they received: equine antithymocyte globu-
lin (n = 29), muromonab CD3 (n = 45), basiliximab with 
corticosteroid maintenance (n = 40) and basiliximab without 
corticosteroid maintenance (n = 69). The incidence of acute 
rejection in the ﬁ  rst three months following transplantation 
was signiﬁ  cantly lower in the basiliximab-treated groups (anti-
thymocyte globulin 31%, muromonab CD3 31%, basiliximab 
with steroid maintenance 17.5% (p   0.005 vs antithymocyte 
globulin), basiliximab without steroid maintenance 14.5% 
(p   0.005 vs antithymocyte globulin and muromonab CD3). 
Patient and graft survival at one year did not differ signiﬁ  -
cantly between the four groups. The length of hospital stay 
and mean cost of induction agent were signiﬁ  cantly less for 
the basiliximab groups (p value not speciﬁ  ed).
Efﬁ  cacy in high-risk groups
The efﬁ  cacy and safety of basiliximab induction was assessed 
in 40 HIV-positive patients undergoing renal transplanta-
tion under concomitant highly active antiretroviral therapy 
(Anil Kumar et al 2005). One- and two-year actuarial patient 
survival was 85% and 82%, respectively, and graft survival 
was 75% and 71%, respectively. The acute rejection rate was 
22%. No patient developed AIDS.
Highly sensitized patients – those who have developed 
high-titer anti-HLA antibodies (indicated by “panel reactive 
antibodies” [PRA]  20%) and are considered at elevated 
risk for allograft rejection – are often treated with induction 
therapy. Jirasiritham and colleagues (2004) compared their 
results in 50 high immunological risk patients induced with 
IL-2R receptor monoclonal antibodies (basiliximab, n = 27, 
or daclizumab, n = 23) with 196 standard risk patients. The 
incidence of acute rejection at three years, graft survival 
and patient survival were not signiﬁ  cantly different between 
the two groups. Tan and colelagues (2005) analyzed their 
results in 56 patients with PRA  30% who were random-
ized to basiliximab (n = 36) or no induction (n = 20). All 
patients were treated with standard triple therapy with 
MMF. At three months the incidence of acute rejection 
was 11.1% in the basiliximab group and 50% in the con-
trol group (p   0.01); but at 12 months renal function was 
equivalent, and there were no differences in patient or 
graft survival. Other studies in highly sensitized patients 
are discussed below.
Basiliximab vs other inducing agents
Several studies have compared the efﬁ  cacy of basiliximab 
with other inducing agents, including lymphocyte-depleting 
drugs and daclizumab. Equine antithymocyte globulin (ATG) 
is uncommonly used nowadays, and the single study in 
which basiliximab was compared with this drug (Sollinger 
et al 2001) will not be discussed further, other than to note 
that the incidence of biopsy-proven rejection was similar 
between the two groups. Comparing muromonab CD3 and 
basiliximab, one large study with 271 patients (Pelletier 
et al 2000) found no differences in acute rejection between 
treatment groups, but three other studies with a total of 368 
patients (Chowdhury et al 2001; Kumar et al 2001; Kode 
et al 2003) reported that basiliximab was associated with 
lower incidences of acute rejection than muromonab CD3 
and fewer adverse advents. Five-year follow-up is available 
from one single-center study (Shoskes et al 2006) in which 52 
recipients were randomized to receive OKT3 or basiliximab; 
the incidence of acute rejection was similar between the two 
groups during the ﬁ  ve-year period. There was a trend for 
greater patient and graft survival in the OKT3 group, although 
the difference was not statistically signiﬁ  cant.
Basiliximab was compared with rabbit ATG plus triple 
immunosuppression with MMF in a randomized unblinded Biologics: Targets & Therapy 2008:2(2) 181
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trial in standard-risk (nonsensitized) patients by Lebranchu 
and colleagues (2002). Cyclosporin microemulsion was 
added immediately following surgery in the basiliximab 
group, but its introduction was delayed by 2–10 days in the 
rabbit ATG group. There were no differences in the incidence 
of acute rejection at six and 12 months, although the small 
group sizes (50 patients/group) precluded a statistical analy-
sis. The incidence of delayed graft function was lower in the 
rabbit ATG group (18% vs 22%, NS). Five-year follow-up is 
now available from this study (Al Najjar et al 2006); patient 
and graft survival were identical. Mean values of serum cre-
atinine at ﬁ  ve years were equivalent. A second randomized 
French study comparing basiliximab and rabbit ATG was 
performed in 105 standard-risk patients treated with delayed 
cyclosporin microemulsion, MMF and corticosteroids 
(Mourad et al 2004). There were no signiﬁ  cant differences 
between groups in the incidence of delayed graft function or 
acute rejection. Cytomegalovirus (CMV) infection was more 
common in the patients who received rabbit ATG than in the 
basiliximab group (41.5% vs 21.2%). It should be mentioned 
that routine prophylaxis against CMV infection was used 
only in CMV-negative patients who received grafts from 
CMV-positive donors.
An interesting aspect of this work involved the sequential 
administration of cyclosporin after the creatinine had fallen 
to 200 μmol/L or on day 8 in the case of delayed graft func-
tion. Delayed graft function (DGF), deﬁ  ned as the need for 
hemodialysis in the ﬁ  rst 3–7 days post-transplant, occurs 
in approximately 30% of renal transplant recipients and is 
associated with signiﬁ  cantly increased risk of acute rejection 
(Sola et al 2004) and increased healthcare costs (Hagenmeyer 
et al 2004). A strategy commonly used to avoid or ameliorate 
DGF is to delay or reduce the dose of the calcineurin inhibitor 
immediately post-transplant, to avoid nephrotoxicity in the 
kidney recovering from the ischemic insult of cold storage. 
Conventional wisdom is that IL-2R antagonists should be 
administered simultaneously with the calcineurin inhibitor, 
whereas lymphocyte-depleting agents can be used without 
calcineurin inhibitors in the ﬁ  rst days after transplantation 
to provide adequate immunosuppression without early neph-
rotoxicity. Nevertheless, in the Mourad study cited above 
in standard-risk patients, basiliximab also allowed delayed 
calcineurin inhibitor use without an increase in acute rejec-
tion. Pallet and colleagues (2006) performed a retrospective 
pilot study in which low-dose cyclosporin was introduced 
sequentially in recipients of expanded criteria donor kidney 
transplants using rabbit ATG (n = 14) or basiliximab (n = 40) 
in association with high-dose MMF and corticosteroids. The 
incidence of acute rejection was 11.3% (7.1% with ATG and 
12.6% with basiliximab). DGF was diagnosed in 54% of 
patients – 10 (72%) in the ATG group and 19 (48%) in the 
basiliximab group (p = 0.03). The duration of DGF was lon-
ger in the ATG-treated patients (p = 0.03). The weight of the 
evidence as summarized in a complete review of the topic by 
Sandrini (2005) indicates that IL-2R antagonists can maintain 
as effective immunosuppression as lymphocyte-depleting 
agents when calcineurin inhibitor administration is reduced 
or delayed, including kidneys from older donors, which are 
at particular risk for DGF (Emparan et al 2003).
In the pediatric age group, Clark and colleagues (2002) 
compared basiliximab, cyclosporin microemulsion and 
corticosteroids with an historical control group treated 
with antilymphocyte globulin, cyclosporin microemulsion, 
azathioprine and corticosteroids; each group consisted of 
42 children who were transplanted consecutively with each 
immunosuppressive protocol. There were no statistical dif-
ferences in the incidence of acute rejection or renal function 
at six months. Fewer CMV infections were observed in 
the basiliximab group (10% vs 19%, NS), particularly in 
children exposed to seropositive combinations (p   0.01). 
In a retrospective analysis from Canada (Acott et al 2001), 
23 children treated with basiliximab induction, cyclosporin, 
azathioprine and corticosteroids were compared to the out-
comes in 27 historical controls treated with rabbit ATG or 
horse antilymphocyte globulin and the same maintenance 
immunosuppressives. Biopsy-conﬁ  rmed acute rejection at 
six months was 9% in the basiliximab group and 33% in the 
lymphocyte-depleting group. Patient and graft survival did 
not differ between groups.
In a retrospective analysis Haririan and colleagues 
(2005) compared their results with basiliximab (n = 52) 
or rabbit ATG (n = 36) in African American kidney trans-
plant recipients, a group at high risk for allograft rejection 
and poor graft survival. The groups were not equal for all 
confounding risk factors; the ATG group tended to have a 
higher proportion of highly sensitized patients, fewer live 
donor transplants, younger age, older donor age, and longer 
duration of dialysis. Nevertheless, after adjusting for these 
variables, graft outcomes and renal function were virtually 
equal between the two groups. The overall incidence of acute 
rejection was lower in the ATG group (14%) compared with 
the basiliximab group (29%), but this difference did not reach 
statistical signiﬁ  cance (p = 0.10).
The largest (n = 278) randomized study comparing 
basiliximab and rabbit ATG in adults was performed in high 
risk recipients (highly sensitized or at risk for delayed graft Biologics: Targets & Therapy 2008:2(2) 182
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function) of deceased donor grafts (Brennan et al 2006). All 
patients were also treated with triple immunosuppression 
including MMF. The primary outcome variable was a com-
posite of acute rejection, delayed graft function, graft loss, 
and death. At 12 months there were no statistical differences 
between groups for the composite endpoint. The rabbit ATG-
treated patients had fewer acute rejections (15.6% vs 25.5%, 
p = 0.02) and required less subsequent antibody therapy for 
acute rejection (1.4% vs 8.0%, p = 0.005), but the incidence 
of graft loss, delayed graft function and death were the same 
between groups. The incidences of all adverse events, serious 
adverse advents (not deﬁ  ned), and cancer were equal between 
the two groups, whereas infections were more common in 
the rabbit ATG-treated group (85.8% vs 75.2%, p = 0.03), 
except for cytomegalovirus (CMV) infection, which in this 
study was more common in the basiliximab-treated group 
(17.5% vs 7.8%, p = 0.02). All patients who had a sero-
positive CMV status before transplantation and patients who 
received CMV positive kidneys were treated prophylactically 
with gancyclovir.
Basiliximab (n = 226) was compared retrospectively with 
alemtuzumab (n = 105) in consecutive recipients of simul-
taneous pancreas-kidney transplants (Sollinger et al 2006); 
maintenance immunosuppression consisted of tacrolimus, 
MMF and prednisone in both groups. Freedom from kidney 
rejection favored the alemtuzumab group (80% vs 68.8%, 
p = 0.0907), whereas freedom from CMV infection favored 
the basiliximab group (83.6% vs 70.7%, p = 0.0021). Patient 
survival, kidney and pancreas grafts survival, pancreas rejec-
tion, and other infectious adverse events including PTLD did 
not differ between groups. Given the low cost of alemtu-
zumab (not speciﬁ  ed), the authors have chosen alemtuzumab 
as the induction drug of choice.
Basiliximab as treatment for acute 
rejection
The only data regarding the use of basiliximab as antirejec-
tion therapy are found in case reports. Eighteen adult solid 
organ transplant recipients (12 kidney, 2 kidney-pancreas 
and 4 liver) with acute rejection were treated on an outpa-
tient basis with two doses of basiliximab, with apparent suc-
cess in 13 patients (Chariat et al 2001). Goh and Lye (2001) 
administered basiliximab to one kidney transplant recipient 
with steroid-resistant rejection who refused muromonab 
CD3 treatment, again apparently with success. Finally, 
Aw and colleagues (2003) treated seven pediatric liver 
transplant recipients with steroid-resistant rejection with 
basiliximab; aspartate aminotransferase levels decreased in 
ﬁ  ve children, who remained rejection-free with a median 
follow-up of 22 months.
Efﬁ  cacy data from meta-analyses
Three meta-analyses of randomized trials have evaluated 
the efﬁ  cacy of IL-2 receptor antagonists (basiliximab, dacli-
zumab, murine anti-Tac and others) in renal transplantation 
(Adu et al 2003; Keown et al 2003; Webster et al 2004). 
Webster and colleagues (2004) included in the analysis 17 
trials in which the inducing agents were compared with 
placebo (n = 2,786) and 15 trials with lymphocyte-depleting 
agents (n = 1,212) through November, 2002. Acute rejec-
tion was signiﬁ  cantly reduced by 34% at six months in 
patients treated with IL-2R antagonists, and these drugs 
also signiﬁ  cantly reduced steroid-resistant rejection. But as 
mentioned previously in the individual studies, there were 
no signiﬁ  cant differences in graft survival at one and three 
years. There were no signiﬁ  cant differences when the IL-
2R antagonists were compared with lymphocyte-depleting 
induction agents in terms of acute rejection. There were also 
no signiﬁ  cant differences in terms of graft loss, patient death, 
CMV infection or malignancy, but the IL-2R antagonists 
were associated with fewer episodes of fever, leukopenia 
and thrombocytopenia. There were no apparent differences 
between basiliximab and daclizumab in terms of efﬁ  cacy 
or side effects.
Drug safety and cost
Individual placebo-controlled trials and the three meta-
analyses of basiliximab efﬁ  cacy have shown that the drug 
is well tolerated, always in the context of induction therapy, 
in the presence of other immunosuppressive agents. Accord-
ing to the meta-analysis by Adu and colleagues (2003), 
which included 1858 analyzed patients treated with dual or 
triple cyclosporin-based immunosuppression, there were no 
signiﬁ  cant differences between IL-2R antagonist induction 
and placebo in terms of overall infections, cytomegalovirus 
infection, or lymphomas or other malignancies at one year. 
The meta-analysis by Webster and colleagues (2004) dem-
onstrated that when IL-2R antagonists were compared with 
polyclonal lymphocyte-depleting agents, there were no sig-
niﬁ  cant differences in terms of mortality, CMV infection or 
malignancy. Fever, leukopenia, and thrombocytopenia were 
less common in the patients treated with IL-2R antagonists. 
The data for CMV infections may have been skewed due 
the large study by Brennan and colleagues (2003; see also 
previous section). If this trial were removed from the analysis, 
CMV infections were much less common in patients treated Biologics: Targets & Therapy 2008:2(2) 183
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with IL-2R antagonists compared with the polyclonals, and 
these results could not be otherwise explained by baseline 
immunosuppression, CMV prophylaxis protocol or trial 
quality. In pediatric renal transplantation recipients Clark 
and colleagues (2002) reported an insigniﬁ  cant difference 
in global CMV infection favoring basiliximab compared 
with antilymphocyte globulin, but these differences were 
statistically signiﬁ  cant in recipients who were seropositive for 
CMV antibodies (0/16 vs 8/156; p   0.01). Also in children 
treated with IL-2R monoclonal antibodies Acott et al (2001) 
demonstrated a tendency towards fewer infections caused by 
human herpes virus type 6 and by Epstein Barr virus and a 
lower incidence of thrombocytopenia and unexplained fever, 
compared to lymphocyte-depleting antibodies.
Importantly, basiliximab is not associated with the ﬁ  rst-
dose reactions and cytokine release phenomena that plague 
muromonab CD3. As mentioned previously, hypersensitivity 
reactions have been reported with the drug, although they 
are rare. Postmarketing surveillance revealed 17 cases of 
hypersensitivity reactions, including anaphylaxis (Baudouin 
et al 2003). The package insert warns that “extreme caution 
should be exercised in all patients previously given Simulect 
when being administered a subsequent course of Simulect.” 
The development of anti-murine antibodies to basiliximab 
or other murine anti-lymphocyte antibody preparations does 
not constitute per se a contraindication to the subsequent 
use of other murine anti-lymphocyte antibody preparations, 
according to the manufacturer.
Several pharmacoeconomic analyses of basiliximab in 
comparison with placebo and with other immunosuppressive 
agents have been performed and are extensively reviewed by 
Chapman and Keating (2003). In brief, in comparison with 
placebo, there were no statistically signiﬁ  cant differences in 
costs in terms of immunosuppressive therapies, total hospi-
talization, laboratory tests, outpatient visits, postoperative 
dialysis, or total costs at six (Walters et al 2003) or 12 (Chilcott 
et al 2002; Lorber et al 2000) months. In all the studies cited, 
basiliximab demonstrated signiﬁ  cant reduction in acute rejec-
tion without increasing overall treatment costs in comparison 
to placebo. Chilcott and colleagues (2002) estimated that the 
cost savings for a single avoided rejection episode in 1996 was 
US$9,823, and six patients in dual therapy needed to be treated 
with basiliximab to avoid a rejection episode in the seventh 
patient during the 12 months following renal transplantation; 
the same group (Walters et al 2003) estimated the cost savings 
per avoided rejection episode was £1650 (1997/1998) and that 
eight patients in triple therapy needed to be treated to avoid 
acute rejection in the ninth patient after six months.
On the other hand, Crompton and colleagues (2003) 
found no economic beneﬁ  t with basiliximab induction in 60 
consecutive adult recipients of live donor kidneys in the ﬁ  rst 
12 months following transplantation. In their retrospective 
analysis the incidence of acute rejection was 15% in the 
control group treated with standard triple therapy without 
induction and 22% in the group treated with basiliximab. 
Mean initial hospitalization charges were significantly 
higher (US$51970 vs US$68,094, 2000, p   0.05) in the 
basiliximab group.
Steroid- and calcineurin inhibitor-
sparing protocols
The reduction or elimination of the most toxic elements of the 
standard protocol – namely corticosteroids and calcineurin 
inhibitors – constitute the most cogent actual argument in 
favor of induction therapy for both low-risk and high-risk 
patients. Approximately 40 published studies can be found 
in the medical literature from the last decade in which basi-
liximab induction has been used with this objective.
Aside from their role as immunosuppressors, cortico-
steroids are associated with a number of hemodynamic 
and metabolic effects which may shorten the survival not 
only of the renal allograft, but also generate risk factors 
which favor cardiovascular disease, the leading cause of 
mortality in kidney transplant recipients (Vincenti 2004). 
Among these risk factors are hypertension, diabetes 
mellitus, and hyperlipidemia. Corticosteroids are also 
associated with cataract formation, aseptic necrosis of 
bone, osteoporosis and cosmetic alterations such as acne 
vulgaris and obesity.
Early steroid withdrawal
Vincenti and colleagues (2003) randomized 83 low-risk renal 
transplant recipients to a triple therapy regimen including 
basiliximab induction, cyclosporin microemulsion, MMF, 
and standard corticosteroid taper or to a rapid steroid with-
drawal protocol in which one dose of methylprednisolone 
is administered preoperatively and four daily doses post-
operatively, followed by complete discontinuation on day 
5. There were no signiﬁ  cant differences in terms of acute 
rejection at six (rapid steroid withdrawal 20% vs standard 
steroids 9%) and 12 months (20% vs 16%), and there were 
no differences between groups for corticosteroid-resistant 
rejection. Graft and patient survival was 100% at twelve 
months for the rapid withdrawal group. Seventy-two per cent 
of the steroid withdrawal group remained off steroids at six 
months post-transplant.Biologics: Targets & Therapy 2008:2(2) 184
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It is apparent that the median time to ﬁ  rst rejection was 
shorter for the rapid withdrawal group in comparison to the 
standard treatment group (31 vs 65 days). This ﬁ  nding may 
represent an advantage for the basiliximab-treated group, 
as acute rejection that occurs before hospital discharge or 
within the ﬁ  rst 60 days after transplantation is associated 
with a reduced risk of chronic allograft nephropathy and 
improved long-term allograft survival, compared to rejection 
that occurs after six months (Basadonna et al 1993; Leggat 
et al 1997).
On the other hand, Woodle and colleagues (2005) per-
formed a multicenter pilot study of rapid steroid withdrawal 
in 77 standard-risk renal transplant recipients, and suggested 
that lymphocyte-depleting agents may be more effective 
for rapid corticosteroid withdrawal recipients, particularly 
those at high immunological risk, because of early accel-
erated rejection – before corticosteroids were completely 
withdrawn – in 7.8% of patients. Koyama and colleagues 
(2006) discontinued corticosteroids in 47 patients 14 days 
after having received ABO-incompatible kidney transplants 
with basiliximab induction; the results were compared to 15 
historical controls treated with standard triple therapy. At six 
months the incidence of acute rejection, graft survival, patient 
survival, and mean serum creatinine were equivalent between 
the two groups. Steroids needed to be resumed in 25 patients 
(53.2%), the motive being acute rejection in 23 patients.
Steroid avoidance
Xiao and colleagues (2003) compared a protocol consist-
ing of basiliximab, cyclosporin microemulsion and MMF 
or sirolimus (n = 42) with a protocol consisting of the same 
drugs plus standard corticosteroids (n = 32) and found no 
differences in the incidence of acute rejection at two years 
after transplantation (14% vs 12%). There were also no 
signiﬁ  cant differences between the two groups in terms 
of renal function (as assessed by serum creatinine and 
creatinine clearance) at one year after transplantation, or 
graft or patient survival after two years. The same group 
(Kumar et al 2004) is performing a ﬁ  ve-year prospective, 
randomized, controlled trial in 77 standard-risk patients, 
and they have reported their interim results at two years. All 
patients received basiliximab, cyclosporin microemulsion 
and MMF. Steroids were discontinued after 2–7 days in the 
rapid withdrawal group and tapered to 5 mg of prednisone 
by 30 days in the control group. Between groups there were 
no differences in the rates of acute rejection, subclinical 
rejection, renal function, or metabolic parameters, although 
there was a tendency for less new onset diabetes mellitus 
in the rapid withdrawal group. African Americans fared as 
well as non-African Americans. Interestingly, a third of the 
patients in each group received “marginal” kidneys – kidneys 
acquired from older donors, donors affected by hyperten-
sion, diabetes mellitus or mild renal insufﬁ  ciency – and a 
tendency towards higher creatinine levels was observed in 
the rapid withdrawal group compared with controls for the 
recipients of these kidneys.
A multicenter, randomized three-armed study compared 
two near-steroid-free protocols – tacrolimus-basiliximab 
(n = 153) and tacrolimus-MMF (n = 151) – to standard cor-
ticosteroids, tacrolimus and MMF (n = 147; Vitko et al 2005) 
in standard-risk recipients. All patients received a single dose 
of methylprednisolone  500 mg perioperatively; the basil-
iximab-tacrolimus and tacrolimus-MMF groups received no 
further steroids. The incidence of biopsy-conﬁ  rmed rejection 
was signiﬁ  cantly higher in the corticosteroid-free groups 
(basiliximab-tacrolimus 26.1% and MMF-tacrolimus 30.5% 
vs standard therapy 8.2%, p   0.001 for basiliximab vs stan-
dard therapy), and the efﬁ  cacy of basiliximab and tacrolimus 
was similar compared to MMF and tacrolimus. The incidence 
of corticosteroid-resistant rejection, graft survival and patient 
survival were similar among the three groups. Median cre-
atinine clearance at the end of the study was signiﬁ  cantly 
higher with standard triple therapy (65.3 ml/min) compared 
with the corticosteroid-free groups (tacrolimus-MMF 59.4 
ml/min, basiliximab- tacrolimus 55.1 ml/min, p = 0.007). 
The incidence of CMV infection was signiﬁ  cantly lower in 
the basiliximab-tacrolimus group, and there was a tendency 
for improved metabolic status in this group in terms on new-
onset diabetes mellitus and reduced mean concentrations of 
cholesterol.
A randomized, double-blind, multicenter study of 108 
renal transplant recipients compared basiliximab to placebo, 
both in association with cyclosporin microemulsion mono-
therapy (Parrott et al 2005). The requirement for additional 
immunosuppression at 12 months post-transplant, the 
primary endpoint of the study, occurred signiﬁ  cantly less 
frequently in the basiliximab group (54%) compared with 
placebo controls (73%, p = 0.046). The incidence of acute 
rejection was lower in the basiliximab group, though the 
difference was not statistically signiﬁ  cant (29% vs 43%, 
p = 0.16); graft and patient survival did not differ between 
groups at 12 months.
Kaufman and colleagues (2005) retrospectively com-
pared their kidney transplant results from 123 patients 
treated with a single 30 mg dose of alemtuzumab, a 3-day 
course of methylprednisolone (no oral prednisone), low-dose Biologics: Targets & Therapy 2008:2(2) 185
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tacrolimus (12-h blood concentrations of 6–8 ng/ml) and 
MMF to a historical control group of 155 patients in which 
basiliximab was used for induction with the same mainte-
nance immunosuppressive drugs. Immunological risk was 
not speciﬁ  ed; African Americans comprised about 20% of 
each group. During the three-year follow-up, less than 7% of 
the recipients required chronic corticosteroid therapy. There 
were no signiﬁ  cant differences in graft and patient survival 
at one and three years. The incidence of acute rejection at 12 
months was 14.9% for the patients treated with alemtuzumab 
and 13.5% for those treated with basiliximab (NS). Rejection 
in the basiliximab group occurred earlier than those treated 
with alemtuzumab (51 ± 83 days post-transplant vs 148 ± 82 
days). Renal function and type and severity of adverse events 
were similar between the two groups.
In a prospective, randomized, multicenter trial 335 kidney 
transplant recipients were randomized to undergo complete 
steroid avoidance, rapid steroid withdrawal or standard 
steroids, in association with cyclosporin, enteric-coated 
mycophenolate sodium and basiliximab induction (Schena 
et al 2006). At 12 months the primary end-point – glomeru-
lar ﬁ  ltration rate – was equivalent in all three groups on an 
intention-to-treat basis. Biopsy-proven acute rejection was 
more frequent in the steroid avoidance and rapid withdrawal 
groups compared to standard steroids (31.5% (p = 0.004 vs 
standard steroids), 26.1% (p = 0.046 vs standard steroids), 
14.7%, respectively), and the time to ﬁ  rst rejection was also 
the shorter in these groups. The increment in body mass index 
and triglyceride levels were signiﬁ  cantly lower in the rapid 
withdrawal group compared to standard steroids (Vincenti 
et al 2006); fewer patients were treated for hyperglycemia 
in the steroid avoidance group.
Calcineurin inhibitor withdrawal 
or avoidance
Basiliximab has been used in clinical studies with the goal 
of reducing or eliminating the calcineurin inhibitor from 
the standard protocol. Hong and Kahan (2001) compared 
recipients assigned to three treatment groups on the basis 
of their risk for delayed graft function (DGF). Patients at 
high risk for DGF were treated with basiliximab, sirolimus, 
corticosteroids plus low dose cyclosporin microemulsion 
(30% of the full dose) which was delayed until the resolution 
of the DGF (creatinine  2.5 mg/dl; n = 43) or muromonab 
CD3 or ATG, corticosteroids, and delayed cyclosporin 
microemulsion (n = 18). Patients at low risk for DGF were 
treated with basiliximab, corticosteroids and immediate 
cyclosporin microemulsion (n = 21). After 12 months 
there were no signiﬁ  cant differences in terms of patient or 
graft survival among the three groups. The mean dose of 
cyclosporin and corticosteroids was signiﬁ  cantly lower for 
the patients receiving basiliximab and sirolimus than for 
those in the other two treatment groups (p   0.001 for both 
comparisons). A retrospective review from the same insti-
tution (Knight et al 2004) compared patients who received 
basiliximab (n = 115) or rabbit ATG (n = 30) in combination 
with sirolimus, steroids and delayed low-dose cyclosporin 
microemulsion. The patients were stratiﬁ  ed as high immune 
responders (African Americans, retransplant recipients or 
PRA  50%) or low immune responders. The high immune 
responders treated with basiliximab had a higher incidence 
of acute rejection episodes (26%) than those treated with 
rabbit ATG (3%, p = 0.01) or low responders treated with 
basiliximab (10%, p = 0.04). The investigators also observed 
a higher mean creatinine level at three months (p   0.01, 
ANOVA), six months (p = 0.02) and 12 months (p = 0.01) 
in high responders treated with basiliximab compared to 
low responders treated with basiliximab or high responders 
treated with rabbit ATG.
Hamdy and colleagues (2005) randomized 132 live donor 
kidney transplant recipients to receive low-dose tacrolimus 
and sirolimus or sirolimus and MMF without the calcineurin 
inhibitor. Both groups were also treated with basiliximab 
induction and corticosteroids. The incidence of acute rejec-
tion tended to be lower in the calcineurin-free group; there 
were no differences in graft and patient survival. Renal 
function after two years was significantly better in the 
calcineurin-free group, both in terms of serum creatinine 
(p = 0.017) and calculated creatinine clearance (p = 0.005). 
Chan and colleagues (2006) randomized 92 patients to 
receive lower dose vs higher dose tacrolimus in association 
with everolimus, corticosteroids and basiliximab induction. 
At six months there were no differences in terms of acute 
rejection; renal function in terms of creatinine clearance and 
serum creatinine tended to be better in the low maintenance 
tacrolimus group. Finally, Martinez-Mier and colleagues 
(2006) compared a calcineurin inhibitor-free protocol (n = 20) 
consisting of sirolimus, MMF, and corticosteroids to standard 
triple therapy (n = 21) in recipients of live donor kidney 
transplants in a prospective, randomized, intention-to-treat 
trial. Basiliximab was used as induction therapy in the siro-
limus group (n = 8) and the cyclosporin group (n = 3) only 
for patients with greater than three HLA mismatches. None 
of the patients who received basiliximab and who maintained 
sirolimus levels in the target range had acute rejection after 
12 months. One patient in the cyclosporin group had an acute Biologics: Targets & Therapy 2008:2(2) 186
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rejection (p NS). No signiﬁ  cant difference in mean serum 
creatinine were noted after 12 months; the sirolimus group 
had signiﬁ  cantly higher cholesterol and triglyceride levels.
Conclusions
Basiliximab induction signiﬁ  cantly reduces the risk of acute 
cellular rejection in the 12 months following renal transplan-
tation in standard risk adult recipients at a cost equivalent 
to conventional therapy in deceased donor transplants. 
However, in well-powered, carefully controlled trials and in 
the three meta-analyses, the drug did not improve patient or 
graft survival in standard risk patients in the short- or in the 
long-term. Particularly in pediatric patients and in recipients 
of kidneys from live donors, basiliximab has not conferred 
any advantage in terms of rejection prophylaxis or cost.
This review has cited the principal prospective random-
ized controlled trials in which basiliximab was incorporated 
in the study protocol. However, we also included interesting 
smaller prospective and retrospective studies performed in 
patient groups which may eventually beneﬁ  t from anti-CD25 
immunosuppression. In high immunologic risk recipients 
treated with otherwise conventional therapy, basiliximab 
substantially reduces the incidence of acute rejection com-
pared with no induction. It seems to be less effective than 
lymphocyte-depleting antibodies in reducing acute rejection 
in high-risk patients in the short-term, although it is associated 
with fewer infectious and hematological side effects. However, 
clinical evidence for this group of patients is still limited, and a 
longer period of follow-up may be required to discern a clear 
advantage for one induction strategy over the other.
Basiliximab provides adequate immunosuppression to 
allow sequential administration of calcineurin inhibitors. 
Larger prospective studies are needed in older patients and 
in recipients of marginal kidneys to conﬁ  rm the reduction 
of delayed graft function found in the small retrospective 
studies; the same groups of patients appear to fare less well 
with steroid withdrawal, which needs to be further studied. 
Also, we need to confront the issue of IL-2 monoclonal 
antibodies in the treatment of acute rejection. Although these 
pharmaceuticals are approved only for induction, it is clear 
that they are also sporadically used for fragile patients with 
rejection, particularly children.
The current role for basiliximab in the evolution of the 
renal transplant immunosuppressive protocol, however, 
appears to be as induction when corticosteroids are to be with-
drawn rapidly following transplantation or when the calcineu-
rin inhibitor is to be administered at reduced doses or avoided 
in association with a TOR inhibitor in low- and standard-risk 
patients. Although a worthy goal, the data from these small 
studies is equivocal at best. Rejection is more frequent in the 
steroid withdrawal and avoidance groups despite basiliximab 
induction. Although rejection occurs early following trans-
plantation and should be amenable to treatment, it is unclear 
if renal function will be compromised in the long-term. No 
deﬁ  nite conclusion can currently be drawn regarding calci-
neurin inhibitor reduction or elimination using basiliximab 
induction because the studies are too few and the group sizes 
are too small. The future of IL-2 monoclonal antibodies in the 
immunosuppressive armamentarium will depend in part in 
deﬁ  ning those patient characteristics which allow avoidance 
of the most toxic elements of the standard protocol.
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